Qualigan Therapeutics宣布首席执行官和首席财务官退休

2024-10-25 05:32

Qualigen Therapeutics (NASDAQ:QLGN) announced that on September 23, 2024, Michael Poirier, notified the board of directors of his intention to resign as Chief Executive Officer and Chairman of the Board, effective immediately.
On the same date, Christopher Lotz, Chief Financial Officer also tendered his resignation from the company, effective immediately.
Both resignations were attributed to disagreements with the company regarding its future direction and strategic initiatives.
On September 25, 2024, the board of directors appointed Campbell Becher as President of the Company, effective immediately.
On September 26, 2024, the board of directors appointed Kevin Richardson as Interim Chief Executive Officer and Chief Financial Officer as well as a member of the board of directors.
Source: Press Release

More on Qualigen Therapeutics